Anti-epidermal growth factor receptor therapy for glioblastoma in adults.

CONCLUSIONS: In summary, there is no evidence of a demonstrable overall survival benefit with the addition of anti-EGFR therapy in first-line and recurrent glioblastomas. Newer drugs that are specially designed for glioblastoma targets may raise the possibility of success in this population, but data are lacking at present. Future studies should be more selective in pursuing people displaying specific EGFR targets.
PMID: 32395825 [PubMed - in process]

Source: Cochrane Database of Systematic Reviews - May 11, 2020 Category: General Medicine Authors: Lee A, Arasaratnam M, Chan DLH, Khasraw M, Howell VM, Wheeler H Tags: Cochrane Database Syst Rev Source Type: research